PDP1 promotes KRAS mutant colorectal cancer progression by serving as a scaffold for BRAF and MEK1
Cancer Letters · 2024-08 · 597 · 217007
DOI: 10.1016/j.canlet.2024.217007 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Letters, 2024-08. Verfasst von Ming Yuan und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of General Surgery (Colorectal Surgery), The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, 510655, PR China; Gu…. Hauptthemen laut MEDLINE: Colorectal Neoplasms, Disease Progression, MAP Kinase Kinase 1, Proto-Oncogene Proteins B-raf. Die Arbeit wurde bisher 24-mal zitiert (Crossref) und nennt 64 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
The oncogenic role of KRAS in colorectal cancer (CRC) progression is well-established. Despite this, identifying effective therapeutic targets for KRAS-mutated CRC remains a significant challenge. This study identifies pyruvate dehydrogenase phosphatase catalytic subunit 1 (PDP1) as a previously unrecognized yet crucial regulator in the progression of KRAS mutant CRC. A substantial upregulation of PDP1 expression is observed in KRAS mutant CRC cells and tissues compared to wild-type KRAS samples, which correlates with poorer prognosis. Functional experiments elucidate that PDP1 accelerates the malignance of KRAS mutant CRC cells, both in vitro and in vivo. Mechanistically, PDP1 acts as a scaffold, enhancing BRAF and MEK1 interaction and activating the MAPK signaling, thereby promoting CRC progression. Additionally, transcription factor KLF5 is identified as the key regulator for PDP1 upregulation in KRAS mutant CRC. Crucially, targeting PDP1 combined with MAPK inhibitors exhibits an obvious inhibitory effect on KRAS mutant CRC. Overall, PDP1 is underscored as a vital oncogenic driver and promising therapeutic target for KRAS mutant CRC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of General Surgery (Colorectal Surgery), The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, 510655, PR China; Guangdong Provincial Key Laboratory of Colorectal and Pelvic Floor Disea…
- Department of Gastrointestinal Surgery, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, Guangdong, 510288, PR China.
- Department of Gastrointestinal Surgery, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, Guangdong, 510288, PR China. Electronic address: wuxianr5@mail.sysu.edu.cn.
Zitieren
APA
Yuan, M., Zhang, C., Chen, S., Ye, S., Liu, H., Ke, H., Huang, J., Liang, G., Yu, R., Hu, T., Wu, X., & Lan, P. (2024). PDP1 promotes KRAS mutant colorectal cancer progression by serving as a scaffold for BRAF and MEK1. Cancer Letters, 597, 217007. https://doi.org/10.1016/j.canlet.2024.217007
Vancouver
Yuan M, Zhang C, Chen S, Ye S, Liu H, Ke H, et al. PDP1 promotes KRAS mutant colorectal cancer progression by serving as a scaffold for BRAF and MEK1. Cancer Letters. 2024;597:217007. doi:10.1016/j.canlet.2024.217007
BibTeX
@article{Yuan2024,
author = {Yuan, Ming and Zhang, Chi and Chen, Shaopeng and Ye, Shubiao and Liu, Huashan and Ke, Haoxian and Huang, Junfeng and Liang, Guanzhan and Yu, Runfeng and Hu, Tuo and Wu, Xianrui and Lan, Ping},
title = {PDP1 promotes KRAS mutant colorectal cancer progression by serving as a scaffold for BRAF and MEK1},
journal = {Cancer Letters},
year = {2024},
volume = {597},
pages = {217007},
doi = {10.1016/j.canlet.2024.217007}
}
EUVIMED